Furthermore, treatment of A549 and NCI-H292 cells with AG490, a JAK2 inhibitor, reduced FGF2 expression, proving that the JAK2/STAT3 pathway is associated with FGF2 modulation in lung cancer cells [39]. This evidence concerns the gene JAK2 and lung carcinoma.